<?xml version='1.0' encoding='UTF-8'?>
<article doi="10.15252/emmm.202013144"><fig id="38938"><title>.</title><label>Figure 1</label><graphic href="https://api.sourcedata.io/file.php?figure_id=38938"/><sd-panel panel_id="103470">(A) <sd-tag id="sdTag1" source="sdapi" category="disease" entity_type="None" role="None" text="NSCLC" ext_ids="DOID:3908" ext_dbs="" in_caption="True" ext_names="lung non-small cell carcinoma" ext_tax_ids="" ext_tax_names="" ext_urls=" https://identifiers.org/">NSCLC</sd-tag> expressing single site mutants of <sd-tag id="sdTag2" source="sdapi" category="None" entity_type="gene" role="component" text="EGFR" ext_ids="1956" ext_dbs="" in_caption="True" ext_names="EGFR" ext_tax_ids="9606" ext_tax_names="Homo sapiens" ext_urls="http://www.ncbi.nlm.nih.gov/gene/">EGFR</sd-tag>, <sd-tag id="sdTag3" source="sdapi" category="None" entity_type="cell" role="experiment" text="PC9" ext_ids="CVCL_B260" ext_dbs="" in_caption="True" ext_names="PC-9" ext_tax_ids="9606" ext_tax_names="Homo sapiens" ext_urls="https://identifiers.org/cellosaurus:">PC9</sd-tag> (3X10<sup>6</sup>) or <sd-tag id="sdTag4" source="sdapi" category="None" entity_type="cell" role="experiment" text="H3255" ext_ids="CVCL_6831" ext_dbs="" in_caption="True" ext_names="NCI-H3255" ext_tax_ids="9606" ext_tax_names="Homo sapiens" ext_urls="https://identifiers.org/cellosaurus:">H3255</sd-tag> (8X10<sup>6</sup>), were seeded in 10-cm dishes. On the next day, complete media were replaced with media containing <sd-tag id="sdTag5" source="sdapi" category="None" entity_type="tissue" role="component" text="serum" ext_ids="UBERON:0001977" ext_dbs="" in_caption="True" ext_names="serum" ext_tax_ids="" ext_tax_names="" ext_urls="https://www.ebi.ac.uk/ols/ontologies/uberon/terms?iri=http%3A%2F%2Fpurl.obolibrary.org%2Fobo%2FUBERON_">serum</sd-tag> (1%) and the cells were treated for 24 hours with different <sd-tag id="sdTag6" source="sdapi" category="None" entity_type="protein" role="intervention" text="EGFR" ext_ids="P00533" ext_dbs="" in_caption="True" ext_names="EGFR" ext_tax_ids="9606" ext_tax_names="Homo sapiens" ext_urls="https://www.uniprot.org/uniprot/">EGFR</sd-tag>-specific TKIs (<sd-tag id="sdTag7" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag>, 50 nM; <sd-tag id="sdTag8" source="sdapi" category="None" entity_type="molecule" role="intervention" text="osimertinib" ext_ids="CHEBI:90943" ext_dbs="" in_caption="True" ext_names="osimertinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">osimertinib</sd-tag>, 50 nM, or <sd-tag id="sdTag9" source="sdapi" category="None" entity_type="molecule" role="intervention" text="afatinib" ext_ids="CHEBI:61390" ext_dbs="" in_caption="True" ext_names="afatinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">afatinib</sd-tag>, 10 nM), either alone or in combination with 2XmAbs (<sd-tag id="sdTag10" source="sdapi" category="None" entity_type="molecule" role="intervention" text="cetuximab" ext_ids="532611" ext_dbs="" in_caption="True" ext_names="Cetuximab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">cetuximab</sd-tag> and <sd-tag id="sdTag11" source="sdapi" category="None" entity_type="molecule" role="intervention" text="trastuzumab" ext_ids="46507516" ext_dbs="" in_caption="True" ext_names="Trastuzumab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">trastuzumab</sd-tag>, 5 μg/ml each). Thereafter, cells were washed with cold saline and extracted. Proteins were separated using <sd-tag id="sdTag12" source="sdapi" category="assay" entity_type="None" role="None" text="gel electrophoresis" ext_ids="OBI_0600053" ext_dbs="" in_caption="True" ext_names="electrophoresis" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ontobee.org/ontology/OBI?iri=http://purl.obolibrary.org/obo/">gel electrophoresis</sd-tag> and transferred onto <sd-tag id="sdTag17" source="sdapi" category="None" entity_type="molecule" role="component" text="nitrocellulose" ext_ids="CHEBI:53325" ext_dbs="" in_caption="True" ext_names="nitrocellulose" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">nitrocellulose</sd-tag> membranes. After blocking, membranes were incubated overnight with the indicated primary antibodies, followed by incubation with <sd-tag id="sdTag14" source="sdapi" category="None" entity_type="protein" role="reporter" text="horseradish peroxidase" ext_ids="" ext_dbs="" in_caption="True" ext_names="" ext_tax_ids="" ext_tax_names="" ext_urls="">horseradish peroxidase</sd-tag>-conjugated secondary antibodies (60 minutes), and treatment with Clarity™ Western ECL Blotting Substrates (Bio-Rad). ECL signals were detected using the ChemiDoc™ Imaging System (Bio-Rad) and <sd-tag id="sdTag15" source="sdapi" category="assay" entity_type="None" role="None" text="images" ext_ids="OBI_0000185" ext_dbs="" in_caption="True" ext_names="imaging assay" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ontobee.org/ontology/OBI?iri=http://purl.obolibrary.org/obo/">images</sd-tag> were acquired using the ImageLab software. Signals (relative to Control) were quantified and normalized to the signals of <sd-tag id="sdTag16" source="sdapi" category="None" entity_type="protein" role="normalizing" text="GAPDH" ext_ids="" ext_dbs="" in_caption="True" ext_names="" ext_tax_ids="" ext_tax_names="" ext_urls="">GAPDH</sd-tag> (numbers shown below each lane). <graphic href="https://api.sourcedata.io/file.php?panel_id=103470"/></sd-panel><sd-panel panel_id="103471">for 24 hours with different <sd-pretag id="sdPretag1114066880sm" type="geneprod" role="intervention">EGFR</sd-pretag>-specific TKIs (<sd-pretag id="sdPretag924916671sm" type="molecule" role="intervention">erlotinib</sd-pretag>, 50 nM; <sd-pretag id="sdPretag517617726sm" type="molecule" role="intervention">osimertinib</sd-pretag>, 50 nM, or <sd-pretag id="sdPretag1541245816sm" type="molecule" role="intervention">afatinib</sd-pretag>, 10 nM), either alone or in combination with <sd-pretag id="sdPretag902611479sm" type="molecule" role="intervention">2XmAbs</sd-pretag> (<sd-pretag id="sdPretag1024117095sm" type="molecule" role="intervention">cetuximab</sd-pretag> and <sd-pretag id="sdPretag2037416631sd" parent-tag-id="11">trastuzumab</sd-pretag>, 5 μg/ml each). (<strong>B</strong>) <sd-pretag id="sdPretag1382868485sm" type="cell" role="component">PC9</sd-pretag> cells (1X10<sup>6</sup><strong>)</strong> were seeded in 6-well <sd-pretag id="sdPretag1310627101sm" type="tissue" role="component">plates</sd-pretag> and treated After washing with acidic buffer (<sd-pretag id="sdPretag804994685sm" type="molecule" role="intervention">glycine</sd-pretag> 100 mM, <sd-pretag id="sdPretag790290365sm" type="cell" role="component">pH 3</sd-pretag>.0), cells were incubated with fluorescently-labelled antibodies against <sd-pretag id="sdPretag298079560sm" type="geneprod" role="assayed">EGFR</sd-pretag>, <sd-pretag id="sdPretag877075645sm" type="geneprod" role="assayed">HER2</sd-pretag> and <sd-pretag id="sdPretag922656683sm" type="geneprod" role="assayed">HER3</sd-pretag>, and surface expression levels of each receptor were analyzed using <sd-pretag id="sdPretag898841212sm" category="assay">flow cytometry</sd-pretag>. The normalized fluorescence intensity is shown as averages + SEM of four experiments. <graphic href="https://api.sourcedata.io/file.php?panel_id=103471"/></sd-panel><sd-panel panel_id="103472">with different <sd-tag id="sdTag28" source="sdapi" category="None" entity_type="protein" role="intervention" text="EGFR" ext_ids="P00533" ext_dbs="" in_caption="True" ext_names="EGFR" ext_tax_ids="9606" ext_tax_names="Homo sapiens" ext_urls="https://www.uniprot.org/uniprot/">EGFR</sd-tag>-specific TKIs (<sd-tag id="sdTag29" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag>, 50 nM; <sd-tag id="sdTag30" source="sdapi" category="None" entity_type="molecule" role="intervention" text="osimertinib" ext_ids="CHEBI:90943" ext_dbs="" in_caption="True" ext_names="osimertinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">osimertinib</sd-tag>, 50 nM, or <sd-tag id="sdTag31" source="sdapi" category="None" entity_type="molecule" role="intervention" text="afatinib" ext_ids="CHEBI:61390" ext_dbs="" in_caption="True" ext_names="afatinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">afatinib</sd-tag>, 10 nM), either alone or in combination with 2XmAbs (<sd-tag id="sdTag32" source="sdapi" category="None" entity_type="molecule" role="intervention" text="cetuximab" ext_ids="532611" ext_dbs="" in_caption="True" ext_names="Cetuximab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">cetuximab</sd-tag> and <sd-tag id="sdTag33" source="sdapi" category="None" entity_type="molecule" role="intervention" text="trastuzumab" ext_ids="46507516" ext_dbs="" in_caption="True" ext_names="Trastuzumab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">trastuzumab</sd-tag>, 5 μg/ml each). (<strong>C</strong>) <sd-tag id="sdTag34" source="sdapi" category="None" entity_type="cell" role="component" text="PC9" ext_ids="CVCL_B260" ext_dbs="" in_caption="True" ext_names="PC-9" ext_tax_ids="9606" ext_tax_names="Homo sapiens" ext_urls="https://identifiers.org/cellosaurus:">PC9</sd-tag> cells were seeded on coverslips and treated for 24 hours Cells were washed in acidic buffer, fixed in paraformaldehyde (4%) and incubated with specific primary antibodies, followed by an <sd-tag id="sdTag35" source="sdapi" category="None" entity_type="molecule" role="reporter" text="Alexa Fluor 555" ext_ids="CHEBI:52673" ext_dbs="" in_caption="True" ext_names="Alexa Fluor 555" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">Alexa Fluor 555</sd-tag>-conjugated secondary antibody (pseudo colored in green). <sd-tag id="sdTag36" source="sdapi" category="None" entity_type="molecule" role="reporter" text="DAPI" ext_ids="CHEBI:51231" ext_dbs="" in_caption="True" ext_names="DAPI" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">DAPI</sd-tag> (blue) was used to stain <sd-tag id="sdTag37" source="sdapi" category="None" entity_type="subcellular" role="assayed" text="nuclei" ext_ids="GO:0005634" ext_dbs="" in_caption="True" ext_names="nucleus" ext_tax_ids="" ext_tax_names="" ext_urls="http://amigo.geneontology.org/amigo/term/">nuclei</sd-tag>. <sd-tag id="sdTag38" source="sdapi" category="assay" entity_type="None" role="None" text="Images" ext_ids="OBI_0000185" ext_dbs="" in_caption="True" ext_names="imaging assay" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ontobee.org/ontology/OBI?iri=http://purl.obolibrary.org/obo/">Images</sd-tag> were captured using a <sd-tag id="sdTag39" source="sdapi" category="assay" entity_type="None" role="None" text="confocal microscope" ext_ids="BAO_0000453" ext_dbs="" in_caption="True" ext_names="confocal microscopy" ext_tax_ids="" ext_tax_names="" ext_urls="https://bioportal.bioontology.org/ontologies/BAO/?p=classes&amp;conceptid=http%3A%2F%2Fwww.bioassayontology.org%2Fbao%23">confocal microscope</sd-tag> (40X magnification). <graphic href="https://api.sourcedata.io/file.php?panel_id=103472"/></sd-panel></fig><fig id="38940"><title>.</title><label>Figure 2</label><graphic href="https://api.sourcedata.io/file.php?figure_id=38940"/><sd-panel panel_id="103509">PC9 cells (3X10<sup>6</sup>/<sd-pretag id="sdPretag1697435338sm" type="organism" role="component">mouse</sd-pretag>) were subcutaneously implanted in the flanks of <sd-pretag id="sdPretag702747879sm" type="geneprod" role="intervention">CD1</sd-pretag>-nu/nu <sd-pretag id="sdPretag1478840692sm" type="organism" role="component">mice</sd-pretag>. When <sd-pretag id="sdPretag283542031sm" type="tissue" role="component">tumors</sd-pretag> became palpable, <sd-pretag id="sdPretag128976853sm" type="organism" role="component">mice</sd-pretag> were randomized in groups of 5-9 animals and treated for 90 days (grey areas) with <sd-pretag id="sdPretag192686876sm" type="molecule" role="intervention">2XmAbs</sd-pretag> (<sd-pretag id="sdPretag766348336sd" parent-tag-id="50">cetuximab</sd-pretag> plus <sd-pretag id="sdPretag525215410sd" parent-tag-id="11">trastuzumab</sd-pretag>, 0.2 mg/<sd-pretag id="sdPretag1004006698sm" type="organism" role="component">mouse</sd-pretag>/injection), once every three days, or with <sd-pretag id="sdPretag1732076542sm" type="molecule" role="intervention">erlotinib</sd-pretag> (50 mg/kg/day), once per day. Alternatively, <sd-pretag id="sdPretag403460940sm" type="organism" role="component">mice</sd-pretag> were treated with combinations of <sd-pretag id="sdPretag1785351947sm" type="molecule" role="intervention">erlotinib</sd-pretag> (50, 20, 10, 5 or 1 mg/kg) and the two monoclonal antibodies. Following 60 days of treatment reduced the frequency of <sd-pretag id="sdPretag2123846637sm" type="molecule" role="component">erlotinib</sd-pretag> administration to once every other day (underneath dotted line). <sd-pretag id="sdPretag1729518116sd" parent-tag-id="171">Tumor volumes</sd-pretag> (<strong>A</strong>) are shown. <sd-pretag id="sdPretag143451723sm" type="organism" role="component">Mice</sd-pretag> were euthanized when <sd-pretag id="sdPretag208810721sm" type="tissue" role="component">tumor</sd-pretag> size reached 1,500 mm<sup>3</sup>. <graphic href="https://api.sourcedata.io/file.php?panel_id=103509"/></sd-panel><sd-panel panel_id="103510"><sd-tag id="sdTag45" source="sdapi" category="None" entity_type="cell" role="component" text="PC9" ext_ids="CVCL_B260" ext_dbs="" in_caption="True" ext_names="PC-9" ext_tax_ids="9606" ext_tax_names="Homo sapiens" ext_urls="https://identifiers.org/cellosaurus:">PC9</sd-tag> cells (3X10<sup>6</sup>/<sd-tag id="sdTag46" source="sdapi" category="None" entity_type="organism" role="assayed" text="mouse" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mouse</sd-tag>) were subcutaneously implanted in the flanks of <sd-tag id="sdTag47" source="sdapi" category="None" entity_type="gene" role="component" text="CD1" ext_ids="111334" ext_dbs="" in_caption="True" ext_names="Cd1" ext_tax_ids="10090" ext_tax_names="Mus musculus" ext_urls="http://www.ncbi.nlm.nih.gov/gene/">CD1</sd-tag>-nu/nu <sd-tag id="sdTag48" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag>. When tumors became palpable, <sd-tag id="sdTag49" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> were randomized in groups of 5-9 animals and treated for 90 days (grey areas) with 2XmAbs (<sd-tag id="sdTag50" source="sdapi" category="None" entity_type="molecule" role="intervention" text="cetuximab" ext_ids="532611" ext_dbs="" in_caption="True" ext_names="Cetuximab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">cetuximab</sd-tag> plus <sd-tag id="sdTag51" source="sdapi" category="None" entity_type="molecule" role="intervention" text="trastuzumab" ext_ids="46507516" ext_dbs="" in_caption="True" ext_names="Trastuzumab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">trastuzumab</sd-tag>, 0.2 mg/<sd-tag id="sdTag52" source="sdapi" category="None" entity_type="organism" role="assayed" text="mouse" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mouse</sd-tag>/injection), once every three days, or with <sd-tag id="sdTag53" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> (50 mg/kg/day), once per day. Alternatively, <sd-tag id="sdTag54" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> were treated with combinations of <sd-tag id="sdTag55" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> (50, 20, 10, 5 or 1 mg/kg) and the two monoclonal antibodies. Following 60 days of treatment reduced the frequency of <sd-tag id="sdTag56" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> administration to once every other day (underneath dotted line). animal <sd-tag id="sdTag57" source="sdapi" category="assay" entity_type="None" role="None" text="survival" ext_ids="OBI_0000789" ext_dbs="" in_caption="True" ext_names="survival rate" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ontobee.org/ontology/OBI?iri=http://purl.obolibrary.org/obo/">survival</sd-tag> (<strong>B</strong>) are shown. <sd-tag id="sdTag58" source="sdapi" category="None" entity_type="organism" role="assayed" text="Mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">Mice</sd-tag> were euthanized when tumor size reached 1,500 mm<sup>3</sup>. <graphic href="https://api.sourcedata.io/file.php?panel_id=103510"/></sd-panel><sd-panel panel_id="103511">(<strong>C</strong>) Statistical analysis of <sd-pretag id="sdPretag608907161sm" type="tissue" role="component">tumor</sd-pretag> volumes corresponding to the last measurement for each <sd-pretag id="sdPretag87526406sm" type="organism" role="component">mouse</sd-pretag> was performed using one-way ANOVA followed by Tukey's multiple comparison test. <graphic href="https://api.sourcedata.io/file.php?panel_id=103511"/></sd-panel><sd-panel panel_id="103512">(<strong>D</strong>) Shown are <sd-pretag id="sdPretag828675611sm" type="tissue" role="component">tumor</sd-pretag> volumes of individual <sd-pretag id="sdPretag1988074379sm" type="organism" role="component">mice</sd-pretag> of each group. Note that each animal is represented by a different color. The respective numbers of <sd-pretag id="sdPretag1092064806sm" type="tissue" role="component">tumor</sd-pretag>-free <sd-pretag id="sdPretag1186340558sm" type="organism" role="component">mice</sd-pretag> are indicated. The grey areas represent treatment phases and they are followed by drug holidays (blank). <graphic href="https://api.sourcedata.io/file.php?panel_id=103512"/></sd-panel></fig><fig id="38942"><title>.</title><label>Figure 3</label><graphic href="https://api.sourcedata.io/file.php?figure_id=38942"/><sd-panel panel_id="103528">PC9 cells (exon 19 deletion) were subcutaneously implanted in the flank of <sd-pretag id="sdPretag327701270sm" type="geneprod" role="intervention">CD1</sd-pretag>-nu/nu <sd-pretag id="sdPretag1345165771sm" type="organism" role="component">mice</sd-pretag> (3X10<sup>6</sup>/<sd-pretag id="sdPretag2058888388sm" type="organism" role="component">mouse</sd-pretag>). When <sd-pretag id="sdPretag1227524940sm" type="tissue" role="component">tumors</sd-pretag> became palpable, <sd-pretag id="sdPretag763398884sm" type="organism" role="component">mice</sd-pretag> were randomized in groups of 5-9 animals and treated for 90 days (grey areas) with <sd-pretag id="sdPretag1989976446sm" type="molecule" role="intervention">2XmAbs</sd-pretag> (<sd-pretag id="sdPretag1290940621sm" type="molecule" role="intervention">cetuximab</sd-pretag> plus <sd-pretag id="sdPretag527195898sd" parent-tag-id="11">trastuzumab</sd-pretag>, each at 0.1 mg/<sd-pretag id="sdPretag929784687sm" type="organism" role="component">mouse</sd-pretag>/injection) once every three days, or daily with different <sd-pretag id="sdPretag202365699sm" type="geneprod" role="intervention">TKIs</sd-pretag>: <sd-pretag id="sdPretag964531731sd" parent-tag-id="68">osimertinib</sd-pretag> (5 mg/kg), <sd-pretag id="sdPretag1236385141sm" type="molecule" role="intervention">afatinib</sd-pretag> (5 mg/kg) or <sd-pretag id="sdPretag1505891982sm" type="molecule" role="intervention">imatinib</sd-pretag> (100 mg/kg), either alone or in combination with the two antibodies. Following 60 days of treatment, the frequency of <sd-pretag id="sdPretag217735575sm" type="molecule" role="intervention_intervention">TKI</sd-pretag> administration was reduced to once every other day (underneath dotted lines), while mAb treatment remained unaltered. Tumor growth (<strong>A</strong>) are shown. <sd-pretag id="sdPretag389461031sm" type="organism" role="component">Mice</sd-pretag> were euthanized when <sd-pretag id="sdPretag660195993sm" type="tissue" role="component">tumor</sd-pretag> size reached 1,500 mm<sup>3</sup>. <graphic href="https://api.sourcedata.io/file.php?panel_id=103528"/></sd-panel><sd-panel panel_id="103530"><sd-tag id="sdTag60" source="sdapi" category="None" entity_type="cell" role="component" text="PC9" ext_ids="CVCL_B260" ext_dbs="" in_caption="True" ext_names="PC-9" ext_tax_ids="9606" ext_tax_names="Homo sapiens" ext_urls="https://identifiers.org/cellosaurus:">PC9</sd-tag> cells (exon 19 deletion) were subcutaneously implanted in the flank of <sd-tag id="sdTag61" source="sdapi" category="None" entity_type="gene" role="component" text="CD1" ext_ids="111334" ext_dbs="" in_caption="True" ext_names="Cd1" ext_tax_ids="10090" ext_tax_names="Mus musculus" ext_urls="http://www.ncbi.nlm.nih.gov/gene/">CD1</sd-tag>-nu/nu <sd-tag id="sdTag62" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> (3X10<sup>6</sup>/<sd-tag id="sdTag63" source="sdapi" category="None" entity_type="organism" role="assayed" text="mouse" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mouse</sd-tag>). When tumors became palpable, <sd-tag id="sdTag64" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> were randomized in groups of 5-9 animals and treated for 90 days (grey areas) with 2XmAbs (<sd-tag id="sdTag65" source="sdapi" category="None" entity_type="molecule" role="intervention" text="cetuximab" ext_ids="532611" ext_dbs="" in_caption="True" ext_names="Cetuximab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">cetuximab</sd-tag> plus <sd-tag id="sdTag66" source="sdapi" category="None" entity_type="molecule" role="intervention" text="trastuzumab" ext_ids="46507516" ext_dbs="" in_caption="True" ext_names="Trastuzumab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">trastuzumab</sd-tag>, each at 0.1 mg/<sd-tag id="sdTag67" source="sdapi" category="None" entity_type="organism" role="assayed" text="mouse" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mouse</sd-tag>/injection) once every three days, or daily with different TKIs: <sd-tag id="sdTag68" source="sdapi" category="None" entity_type="molecule" role="intervention" text="osimertinib" ext_ids="CHEBI:90943" ext_dbs="" in_caption="True" ext_names="osimertinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">osimertinib</sd-tag> (5 mg/kg), <sd-tag id="sdTag69" source="sdapi" category="None" entity_type="molecule" role="intervention" text="afatinib" ext_ids="CHEBI:61390" ext_dbs="" in_caption="True" ext_names="afatinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">afatinib</sd-tag> (5 mg/kg) or <sd-tag id="sdTag70" source="sdapi" category="None" entity_type="molecule" role="intervention" text="imatinib" ext_ids="CHEBI:45783" ext_dbs="" in_caption="True" ext_names="imatinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">imatinib</sd-tag> (100 mg/kg), either alone or in combination with the two antibodies. Following 60 days of treatment, the frequency of TKI administration was reduced to once every other day (underneath dotted lines), while mAb treatment remained unaltered. animal <sd-tag id="sdTag71" source="sdapi" category="assay" entity_type="None" role="None" text="survival" ext_ids="OBI_0000789" ext_dbs="" in_caption="True" ext_names="survival rate" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ontobee.org/ontology/OBI?iri=http://purl.obolibrary.org/obo/">survival</sd-tag> (<strong>B</strong>) are shown. <sd-tag id="sdTag72" source="sdapi" category="None" entity_type="organism" role="assayed" text="Mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">Mice</sd-tag> were euthanized when tumor size reached 1,500 mm<sup>3</sup>. <graphic href="https://api.sourcedata.io/file.php?panel_id=103530"/></sd-panel><sd-panel panel_id="103532">(<strong>C</strong>) Statistical analysis of <sd-pretag id="sdPretag1023473737sm" type="tissue" role="component">tumor</sd-pretag> volumes corresponding to the last measurement for each <sd-pretag id="sdPretag1694405625sm" type="organism" role="component">mouse</sd-pretag> was performed using one-way ANOVA followed by Tukey's multiple comparison test. <graphic href="https://api.sourcedata.io/file.php?panel_id=103532"/></sd-panel><sd-panel panel_id="103533">(<strong>D</strong>) Shown are <sd-pretag id="sdPretag100898560sm" type="tissue" role="component">tumor</sd-pretag> volumes corresponding to individual animals of each group. The numbers of <sd-pretag id="sdPretag494689662sm" type="organism" role="component">mice</sd-pretag> with undetectable <sd-pretag id="sdPretag1049775992sm" type="tissue" role="component">tumors</sd-pretag> are indicated. The grey areas represent treatment phases and they are followed by drug holidays (blank). <graphic href="https://api.sourcedata.io/file.php?panel_id=103533"/></sd-panel></fig><fig id="38944"><title>.</title><label>Figure 4</label><graphic href="https://api.sourcedata.io/file.php?figure_id=38944"/><sd-panel panel_id="103541">CD1-nu/nu <sd-pretag id="sdPretag647592233sm" type="organism" role="component">mice</sd-pretag> carrying <sd-pretag id="sdPretag1923687442sm" type="cell" role="component">PC9</sd-pretag> <sd-pretag id="sdPretag143942957sm" type="organism" role="component">xenografts</sd-pretag> were divided in groups (2-3 <sd-pretag id="sdPretag650788228sm" type="organism" role="component">mice</sd-pretag>/group) and treated for seven days with different <sd-pretag id="sdPretag1463245498sm" type="molecule" role="intervention">TKIs</sd-pretag>: <sd-pretag id="sdPretag134536319sm" type="molecule" role="intervention">erlotinib</sd-pretag> (50 mg/kg or 20 mg/kg), <sd-pretag id="sdPretag1718285510sm" type="molecule" role="intervention">osimertinib</sd-pretag> (5 mg/kg) or <sd-pretag id="sdPretag925106432sm" type="molecule" role="intervention">afatinib</sd-pretag> (5 mg/kg), either alone or in combination with <sd-pretag id="sdPretag1119910229sm" type="molecule" role="intervention">2XmAbs</sd-pretag> (<sd-pretag id="sdPretag1121475509sd" parent-tag-id="50">cetuximab</sd-pretag> and <sd-pretag id="sdPretag548356755sd" parent-tag-id="11">trastuzumab</sd-pretag>, each at 0.1 mg/<sd-pretag id="sdPretag1790589144sm" type="organism" role="component">mouse</sd-pretag>/injection). when singly applied used <sd-pretag id="sdPretag1209272038sm" type="molecule" role="intervention">erlotinib</sd-pretag> at 50 mg/kg. (<strong>A</strong>) Shown are fold changes in <sd-pretag id="sdPretag1910230896sm" type="tissue" role="component">tumor</sd-pretag> volume at day 7 of treatment. The horizontal line indicates no change in <sd-pretag id="sdPretag2098202027sm" type="tissue" role="component">tumor</sd-pretag> volume (fold change) between days 0 and 7 of treatment. <graphic href="https://api.sourcedata.io/file.php?panel_id=103541"/></sd-panel><sd-panel panel_id="103542"><sd-tag id="sdTag74" source="sdapi" category="None" entity_type="gene" role="component" text="CD1" ext_ids="111334" ext_dbs="" in_caption="True" ext_names="Cd1" ext_tax_ids="10090" ext_tax_names="Mus musculus" ext_urls="http://www.ncbi.nlm.nih.gov/gene/">CD1</sd-tag>-nu/nu <sd-tag id="sdTag75" source="sdapi" category="None" entity_type="organism" role="component" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> carrying <sd-tag id="sdTag76" source="sdapi" category="None" entity_type="cell" role="component" text="PC9" ext_ids="CVCL_B260" ext_dbs="" in_caption="True" ext_names="PC-9" ext_tax_ids="9606" ext_tax_names="Homo sapiens" ext_urls="https://identifiers.org/cellosaurus:">PC9</sd-tag> xenografts were divided in groups (2-3 <sd-tag id="sdTag78" source="sdapi" category="None" entity_type="organism" role="component" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag>/group) and treated for seven days with different TKIs: <sd-tag id="sdTag79" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> (50 mg/kg or 20 mg/kg), <sd-tag id="sdTag80" source="sdapi" category="None" entity_type="molecule" role="intervention" text="osimertinib" ext_ids="CHEBI:90943" ext_dbs="" in_caption="True" ext_names="osimertinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">osimertinib</sd-tag> (5 mg/kg) or <sd-tag id="sdTag81" source="sdapi" category="None" entity_type="molecule" role="intervention" text="afatinib" ext_ids="CHEBI:61390" ext_dbs="" in_caption="True" ext_names="afatinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">afatinib</sd-tag> (5 mg/kg), either alone or in combination with 2XmAbs (<sd-tag id="sdTag82" source="sdapi" category="None" entity_type="molecule" role="intervention" text="cetuximab" ext_ids="532611" ext_dbs="" in_caption="True" ext_names="Cetuximab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">cetuximab</sd-tag> and <sd-tag id="sdTag83" source="sdapi" category="None" entity_type="molecule" role="intervention" text="trastuzumab" ext_ids="46507516" ext_dbs="" in_caption="True" ext_names="Trastuzumab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">trastuzumab</sd-tag>, each at 0.1 mg/<sd-tag id="sdTag84" source="sdapi" category="None" entity_type="organism" role="component" text="mouse" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mouse</sd-tag>/injection). when singly applied used <sd-tag id="sdTag85" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> at 50 mg/kg. (<strong>B</strong>) After treatment, all <sd-tag id="sdTag86" source="sdapi" category="None" entity_type="organism" role="component" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> were sacrificed and tumors extracted. Protein extracts were resolved by means of <sd-tag id="sdTag87" source="sdapi" category="assay" entity_type="None" role="None" text="electrophoresis" ext_ids="OBI_0600053" ext_dbs="" in_caption="True" ext_names="electrophoresis" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ontobee.org/ontology/OBI?iri=http://purl.obolibrary.org/obo/">electrophoresis</sd-tag> and transfer to <sd-tag id="sdTag88" source="sdapi" category="None" entity_type="molecule" role="component" text="nitrocellulose" ext_ids="CHEBI:53325" ext_dbs="" in_caption="True" ext_names="nitrocellulose" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">nitrocellulose</sd-tag> membranes, which were later incubated overnight with the indicated antibodies. This was followed by incubation with <sd-tag id="sdTag89" source="sdapi" category="None" entity_type="protein" role="reporter" text="peroxidase" ext_ids="" ext_dbs="" in_caption="True" ext_names="" ext_tax_ids="" ext_tax_names="" ext_urls="">peroxidase</sd-tag>-conjugated secondary antibodies. Signals were detected using Chemidoc<sup>TM</sup> (from Bio-Rad), quantified and normalized to the signals of <sd-tag id="sdTag90" source="sdapi" category="None" entity_type="protein" role="normalizing" text="GAPDH" ext_ids="" ext_dbs="" in_caption="True" ext_names="" ext_tax_ids="" ext_tax_names="" ext_urls="">GAPDH</sd-tag> or <sd-tag id="sdTag91" source="sdapi" category="None" entity_type="protein" role="normalizing" text="tubulin" ext_ids="" ext_dbs="" in_caption="True" ext_names="" ext_tax_ids="" ext_tax_names="" ext_urls="">tubulin</sd-tag> (numbers shown below each lane). <graphic href="https://api.sourcedata.io/file.php?panel_id=103542"/></sd-panel></fig><fig id="38946"><title>.</title><label>Figure 5</label><graphic href="https://api.sourcedata.io/file.php?figure_id=38946"/><sd-panel panel_id="103547">A, <strong>B</strong> <sd-tag id="sdTag107" source="sdapi" category="None" entity_type="cell" role="assayed" text="PC9" ext_ids="CVCL_B260" ext_dbs="" in_caption="True" ext_names="PC-9" ext_tax_ids="9606" ext_tax_names="Homo sapiens" ext_urls="https://identifiers.org/cellosaurus:">PC9</sd-tag> cells (3X10<sup>6</sup>/<sd-tag id="sdTag108" source="sdapi" category="None" entity_type="organism" role="assayed" text="mouse" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mouse</sd-tag>) were subcutaneously injected in the flanks of <sd-tag id="sdTag109" source="sdapi" category="None" entity_type="gene" role="component" text="CD1" ext_ids="111334" ext_dbs="" in_caption="True" ext_names="Cd1" ext_tax_ids="10090" ext_tax_names="Mus musculus" ext_urls="http://www.ncbi.nlm.nih.gov/gene/">CD1</sd-tag>-nu/nu <sd-tag id="sdTag110" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag>. When tumors reached a volume of approximately 500 mm<sup>3</sup>, <sd-tag id="sdTag111" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> were treated daily with <sd-tag id="sdTag112" source="sdapi" category="None" entity_type="molecule" role="experiment" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> (50 mg/kg, blue area; panel <strong>A</strong>) or with <sd-tag id="sdTag113" source="sdapi" category="None" entity_type="molecule" role="experiment" text="osimertinib" ext_ids="CHEBI:90943" ext_dbs="" in_caption="True" ext_names="osimertinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">osimertinib</sd-tag> (5 mg/kg, grey area; panel <strong>B</strong>) using oral gavage. Initially, all tumors displayed stable disease or they regressed, but eventually all started relapsing. Once relapsing tumors reached 800 mm<sup>3</sup>, while under <sd-tag id="sdTag114" source="sdapi" category="None" entity_type="molecule" role="experiment" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> or <sd-tag id="sdTag115" source="sdapi" category="None" entity_type="molecule" role="experiment" text="osimertinib" ext_ids="CHEBI:90943" ext_dbs="" in_caption="True" ext_names="osimertinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">osimertinib</sd-tag> treatment, we supplemented the treatment with a combination of 2XmAbs (<sd-tag id="sdTag116" source="sdapi" category="None" entity_type="molecule" role="intervention" text="cetuximab" ext_ids="532611" ext_dbs="" in_caption="True" ext_names="Cetuximab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">cetuximab</sd-tag> and <sd-tag id="sdTag117" source="sdapi" category="None" entity_type="molecule" role="intervention" text="trastuzumab" ext_ids="46507516" ext_dbs="" in_caption="True" ext_names="Trastuzumab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">trastuzumab</sd-tag>, each at 0.1 mg/<sd-tag id="sdTag118" source="sdapi" category="None" entity_type="organism" role="assayed" text="mouse" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mouse</sd-tag>/injection; twice a week) plus either <sd-tag id="sdTag119" source="sdapi" category="None" entity_type="molecule" role="experiment" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> (50 mg/kg; A, red area) or <sd-tag id="sdTag120" source="sdapi" category="None" entity_type="molecule" role="experiment" text="osimertinib" ext_ids="CHEBI:90943" ext_dbs="" in_caption="True" ext_names="osimertinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">osimertinib</sd-tag> (5 mg/kg; B, orange area). <sd-tag id="sdTag171" source="sdapi" category="assay" entity_type="None" role="None" text="Tumor volumes" ext_ids="" ext_dbs="" in_caption="True" ext_names="" ext_tax_ids="" ext_tax_names="" ext_urls="">Tumor volumes</sd-tag> of individual <sd-tag id="sdTag121" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> are shown. <graphic href="https://api.sourcedata.io/file.php?panel_id=103547"/></sd-panel></fig><fig id="38948"><title>.</title><label>Figure 6</label><graphic href="https://api.sourcedata.io/file.php?figure_id=38948"/><sd-panel panel_id="103552">A, B NSG <sd-tag id="sdTag124" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> were pre-implanted with tumor fragments derived from two different PDX models: (A) TM00199 (L858R-<sd-tag id="sdTag125" source="sdapi" category="None" entity_type="gene" role="component" text="EGFR" ext_ids="13649" ext_dbs="" in_caption="True" ext_names="Egfr" ext_tax_ids="10090" ext_tax_names="Mus musculus" ext_urls="http://www.ncbi.nlm.nih.gov/gene/">EGFR</sd-tag>; from The Jackson Laboratory) or (<strong>B</strong>) TM00193 (E746_A750 del-<sd-tag id="sdTag126" source="sdapi" category="None" entity_type="gene" role="component" text="EGFR" ext_ids="13649" ext_dbs="" in_caption="True" ext_names="Egfr" ext_tax_ids="10090" ext_tax_names="Mus musculus" ext_urls="http://www.ncbi.nlm.nih.gov/gene/">EGFR</sd-tag>; from The Jackson Laboratory). Once tumors reached approximately 300 mm<sup>3</sup>, <sd-tag id="sdTag127" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> were treated with monoclonal antibodies (2XmAbs, <sd-tag id="sdTag128" source="sdapi" category="None" entity_type="molecule" role="intervention" text="cetuximab" ext_ids="532611" ext_dbs="" in_caption="True" ext_names="Cetuximab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">cetuximab</sd-tag> plus <sd-tag id="sdTag129" source="sdapi" category="None" entity_type="molecule" role="intervention" text="trastuzumab" ext_ids="46507516" ext_dbs="" in_caption="True" ext_names="Trastuzumab" ext_tax_ids="" ext_tax_names="" ext_urls="https://pubchem.ncbi.nlm.nih.gov/substance/">trastuzumab</sd-tag>, 200μg/injection) twice a week, or with <sd-tag id="sdTag130" source="sdapi" category="None" entity_type="protein" role="component" text="EGFR" ext_ids="Q01279" ext_dbs="" in_caption="True" ext_names="Egfr" ext_tax_ids="10090" ext_tax_names="Mus musculus" ext_urls="https://www.uniprot.org/uniprot/">EGFR</sd-tag> TKIs, <sd-tag id="sdTag131" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> (50mg/kg) or <sd-tag id="sdTag132" source="sdapi" category="None" entity_type="molecule" role="intervention" text="osimertinib" ext_ids="CHEBI:90943" ext_dbs="" in_caption="True" ext_names="osimertinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">osimertinib</sd-tag> (10mg/kg) daily. Alternatively, <sd-tag id="sdTag133" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> were treated with a combination of 2XmAbs and either <sd-tag id="sdTag134" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> or <sd-tag id="sdTag135" source="sdapi" category="None" entity_type="molecule" role="intervention" text="osimertinib" ext_ids="CHEBI:90943" ext_dbs="" in_caption="True" ext_names="osimertinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">osimertinib</sd-tag>, for either 32 days (A) or 42 days (B). Tumor growth was monitored twice a week. the antibodies were injected into the peritoneum and the TKIs were delivered orally. The figure shows <sd-tag id="sdTag172" source="sdapi" category="assay" entity_type="None" role="None" text="tumor volumes" ext_ids="" ext_dbs="" in_caption="True" ext_names="" ext_tax_ids="" ext_tax_names="" ext_urls="">tumor volumes</sd-tag> of individual <sd-tag id="sdTag136" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> and the respective <sd-tag id="sdTag137" source="sdapi" category="assay" entity_type="None" role="None" text="survival curves" ext_ids="OBI_0000889" ext_dbs="" in_caption="True" ext_names="survival curve" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ontobee.org/ontology/OBI?iri=http://purl.obolibrary.org/obo/">survival curves</sd-tag> (right hand panels). The grey areas mark time windows of animal treatment. <graphic href="https://api.sourcedata.io/file.php?panel_id=103552"/></sd-panel><sd-panel panel_id="103553">(<strong>C</strong>) <sd-pretag id="sdPretag443292416sm" type="organism" role="component">Mice</sd-pretag> presented in the <sd-pretag id="sdPretag1720715099sd" parent-tag-id="146">erlotinib</sd-pretag>+2XmAbs group were re-treated with the same drug combination (<sd-pretag id="sdPretag1162117187sm" type="molecule" role="intervention">2XmAbs</sd-pretag> plus <sd-pretag id="sdPretag1854915531sm" type="molecule" role="intervention">erlotinib</sd-pretag>) after a holiday period (&gt;136 days), during which they received no treatment. Note that different colors identify individual <sd-pretag id="sdPretag2010435350sm" type="organism" role="component">mice</sd-pretag> <graphic href="https://api.sourcedata.io/file.php?panel_id=103553"/></sd-panel></fig><fig id="38949"><title>.</title><label>Figure 7</label><graphic href="https://api.sourcedata.io/file.php?figure_id=38949"/><sd-panel panel_id="103554">(A) A scheme depicting the experimental plan and longitudinal sampling. <graphic href="https://api.sourcedata.io/file.php?panel_id=103554"/></sd-panel><sd-panel panel_id="103555">(<strong>B</strong>) For <sd-tag id="sdTag139" source="sdapi" category="assay" entity_type="None" role="None" text="RNAseq analyses" ext_ids="OBI_0001271" ext_dbs="" in_caption="True" ext_names="RNA-seq assay" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ontobee.org/ontology/OBI?iri=http://purl.obolibrary.org/obo/">RNAseq analyses</sd-tag>, <sd-tag id="sdTag140" source="sdapi" category="None" entity_type="cell" role="component" text="PC9" ext_ids="CVCL_B260" ext_dbs="" in_caption="True" ext_names="PC-9" ext_tax_ids="9606" ext_tax_names="Homo sapiens" ext_urls="https://identifiers.org/cellosaurus:">PC9</sd-tag> cells (3X10<sup>6</sup>/<sd-tag id="sdTag141" source="sdapi" category="None" entity_type="organism" role="component" text="mouse" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mouse</sd-tag>) were subcutaneously injected in the flanks of 13 <sd-tag id="sdTag142" source="sdapi" category="None" entity_type="gene" role="component" text="CD1" ext_ids="111334" ext_dbs="" in_caption="True" ext_names="Cd1" ext_tax_ids="10090" ext_tax_names="Mus musculus" ext_urls="http://www.ncbi.nlm.nih.gov/gene/">CD1</sd-tag>-nu/nu <sd-tag id="sdTag143" source="sdapi" category="None" entity_type="organism" role="component" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag>. When tumors reached 500 mm<sup>3</sup>, <sd-tag id="sdTag144" source="sdapi" category="None" entity_type="organism" role="component" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> were treated daily with <sd-tag id="sdTag145" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> (50 mg/kg). Once tumors that initially responded to <sd-tag id="sdTag146" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> monotherapy started relapsing and reached 800 mm<sup>3</sup>, we switched to a combination of 2XmAbs plus <sd-tag id="sdTag147" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> (50 mg/kg). The respective tumor volumes were sacrificed when tumor volumes reached approximately 500 mm<sup>3</sup> <sd-tag id="sdTag157" source="sdapi" category="None" entity_type="organism" role="component" text="Mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">Mice</sd-tag> responding to <sd-tag id="sdTag148" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> (N=3) were sacrificed after one week of treatment <sd-tag id="sdTag149" source="sdapi" category="None" entity_type="organism" role="component" text="Mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">Mice</sd-tag> resistant to <sd-tag id="sdTag150" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag> (N=3) were sacrificed when tumor volumes reached 800 mm<sup>3</sup> whereas <sd-tag id="sdTag151" source="sdapi" category="None" entity_type="organism" role="component" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> responding to <sd-tag id="sdTag152" source="sdapi" category="None" entity_type="molecule" role="intervention" text="erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">erlotinib</sd-tag>+2XmAbs (N=2) were sacrificed after one week of treatment RNA was extracted from all 13 tumors and utilized for <sd-tag id="sdTag153" source="sdapi" category="assay" entity_type="None" role="None" text="RNA-seq analysis" ext_ids="OBI_0001271" ext_dbs="" in_caption="True" ext_names="RNA-seq assay" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ontobee.org/ontology/OBI?iri=http://purl.obolibrary.org/obo/">RNA-seq analysis</sd-tag>. Differentially expressed (DE) genes in the <sd-tag id="sdTag154" source="sdapi" category="None" entity_type="molecule" role="intervention" text="Erlotinib" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">Erlotinib</sd-tag> (<sd-tag id="sdTag155" source="sdapi" category="None" entity_type="molecule" role="intervention" text="Er" ext_ids="CHEBI:114785" ext_dbs="" in_caption="True" ext_names="erlotinib" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">Er</sd-tag>)+2XmAbs arm compared to the Control group are presented in the heatmap. <graphic href="https://api.sourcedata.io/file.php?panel_id=103555"/></sd-panel><sd-panel panel_id="103556">(<strong>C</strong>) Protein extracts were prepared from all tumors and analyzed using <sd-tag id="sdTag158" source="sdapi" category="assay" entity_type="None" role="None" text="immunoblotting" ext_ids="OBI_0001978" ext_dbs="" in_caption="True" ext_names="immunoblot assay" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ontobee.org/ontology/OBI?iri=http://purl.obolibrary.org/obo/">immunoblotting</sd-tag>, as indicated. Signals were quantified and normalized to the signals of <sd-tag id="sdTag159" source="sdapi" category="None" entity_type="protein" role="normalizing" text="GAPDH" ext_ids="" ext_dbs="" in_caption="True" ext_names="" ext_tax_ids="" ext_tax_names="" ext_urls="">GAPDH</sd-tag> (numbers shown below each lane). <graphic href="https://api.sourcedata.io/file.php?panel_id=103556"/></sd-panel><sd-panel panel_id="103557">(<strong>D</strong>) Summary model: ERK and AKT phosphorylate the transcription factor <sd-pretag id="sdPretag272304081sm" type="geneprod" role="component">FOXO3a</sd-pretag>, thereby dampen its ability to downregulate <sd-pretag id="sdPretag1620233098sm" type="geneprod" role="component">FOXM1</sd-pretag>. The combination of <sd-pretag id="sdPretag1047624025sm" type="molecule" role="intervention">erlotinib</sd-pretag>, <sd-pretag id="sdPretag620848315sd" parent-tag-id="50">cetuximab</sd-pretag> and <sd-pretag id="sdPretag1177973954sd" parent-tag-id="11">trastuzumab</sd-pretag> overcomes TKI resistance by inhibiting <sd-pretag id="sdPretag259479550sm" type="geneprod" role="intervention">ERK</sd-pretag>, AKT and <sd-pretag id="sdPretag1615465658sm" type="geneprod" role="intervention">FOXM1</sd-pretag> transcription. This downregulates several <sd-pretag id="sdPretag958595637sm" type="geneprod" role="intervention">FOXM1</sd-pretag> target genes, such as <sd-pretag id="sdPretag812249732sm" type="geneprod" role="assayed">cyclinB1</sd-pretag>, <sd-pretag id="sdPretag738406497sm" type="geneprod" role="assayed">AURKA</sd-pretag>, <sd-pretag id="sdPretag8259770sm" type="geneprod" role="assayed">CENPA</sd-pretag>, <sd-pretag id="sdPretag1487291668sm" type="geneprod" role="assayed">BIRC5</sd-pretag>, <sd-pretag id="sdPretag1549349794sm" type="geneprod" role="assayed">PRC1</sd-pretag> and <sd-pretag id="sdPretag436203314sm" type="geneprod" role="assayed">KIF4A</sd-pretag>. All these genes play an essential role in the late steps of the cell cycle, primarily mitosis and cytokinesis, and their downregulation results in inhibition of cell proliferation. The lower panel refers to the <sd-pretag id="sdPretag625036189sm" type="tissue" role="component">tumor</sd-pretag> samples analyzed in B and shows the calculated fold changes of a gene module repressed after treatment with <sd-pretag id="sdPretag1619893714sm" type="molecule" role="intervention">erlotinib</sd-pretag>+<sd-pretag id="sdPretag1889063888sm" type="molecule" role="intervention">2XmAbs</sd-pretag>. <graphic href="https://api.sourcedata.io/file.php?panel_id=103557"/></sd-panel></fig></article>